Abstract
Centrally acting (moxonidine) and peripherally acting (metoprolol) sympatholytic agents might have different actions upon penile circulation in hypertensive men with erectile dysfunction. A total of 11 nonsmoking, hypertensive but otherwise healthy men with erectile dysfunction were studied after 8 weeks on moxonidine monotherapy (0.4 mg per day, increased to 0.6 mg if needed) and then after 8 weeks of metoprolol monotherapy (100 mg per day, increased to 200 mg if needed) in a crossover design. At the end of each treatment phase, the subjects were asked about their subjective erectile capacity (nocturnal and coital erections), and resting and stimulated (after intracavernosal injection of a mixture of alprostadil and phentolamine) penile deep artery diameters and systolic peak velocities were measured by color Doppler ultrasonography. There were no significant differences in blood pressure after either therapy. The change from earlier antihypertensive therapy, moxonidine produced significant subjective amelioration of sexual dysfunction in 9/11 of the men (P<0.001), whereas 9/11 returned to impaired dysfunction after crossover to metoprolol treatment. Resting and stimulated deep penile diameters and peak systolic velocities were higher after moxonidine treatment compared with metoprolol (diameters: P<0.004, P<0.0001; velocities: P<0.008, P<0.038). The centrally acting sympatholytic agent moxonidine seems to improve erectile function both subjectively and objectively and has a better effect on penile circulation compared with the peripherally acting sympatholytic agent metoprolol.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lundberg PO, Biriell C . Impotence—the drug risk factor. Int J Impot Res 1993; 5: 237–239.
Keene LC, Davies PH . Drug related erectile dysfunction. Adverse Drug React Toxicol Rev 1999; 18: 5–24.
Fogari R et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertension 2001; 14: 27–31.
Grimm RH et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8–14.
Meinhardt WP et al. The influence of medication on erectile function. Int J Impot Res 1997; 9: 17–26.
Kifor I et al. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920–1925.
Kayigil O, Ergen A . Caverno-occlusive and autonomic dysfunction: a new concept in young patients. Eur Urol 1998; 34: 124–127.
Ernsberger PR, Westbrooks KL, Christen MO, Schäfer SG . A second generation of centrally acting antihypertensive agents act on putative imidazoline-II receptors. J Cardiovasc Pharmacol 1992; 20: 1–10.
Ziegler D et al. Pharmacology of moxonidine, an I1-imidazoline agonist. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S26–S37.
Haenni A, Lithell H . Moxonidine improves insulin sensitivity in insulin resistant hypertensives. J Hypertension 1999; 17 (Suppl 3): S29–S35.
Acknowledgements
This work was supported by the Finnish Hypertension Society and Solvay Pharma /Algol.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Piha, J., Kaaja, R. Effects of moxonidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction: results of a pilot study. Int J Impot Res 15, 287–289 (2003). https://doi.org/10.1038/sj.ijir.3901007
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901007
Keywords
This article is cited by
-
A multidisciplinary approach to assess erectile dysfunction in high-risk cardiovascular patients
International Journal of Impotence Research (2005)